S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

IO Biotech Stock Forecast, Price & News

-0.17 (-3.64%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
2,491 shs
Average Volume
41,295 shs
Market Capitalization
$129.67 million
P/E Ratio
Dividend Yield
Price Target

IO Biotech MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
355.6% Upside
$20.50 Price Target
Short Interest
0.03% of Float Sold Short
Dividend Strength
News Sentiment
0.93mentions of IO Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.51) to ($2.27) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.01 out of 5 stars

Medical Sector

495th out of 1,427 stocks

Pharmaceutical Preparations Industry

234th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive IOBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter.

IO Biotech logo

About IO Biotech (NASDAQ:IOBT) Stock

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IOBT Stock News Headlines

IO Biotech Announces First Quarter Results for 2022
IO Biotech Hosting Key Opinion Leader Webinar Series
IO Biotech Inc (IOBT)
IO Biotech reports FY results
SUNW, CEI and HNRG among mid-day movers
IO Biotech Trading 21% Higher
IO Biotech, Inc. (IOBT)
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$7.35 per share


Free Float
Market Cap
$129.67 million
Not Optionable

IO Biotech Frequently Asked Questions

Should I buy or sell IO Biotech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IO Biotech stock.
View analyst ratings for IO Biotech
or view top-rated stocks.

What is IO Biotech's stock price forecast for 2022?

3 Wall Street analysts have issued 12 month price targets for IO Biotech's shares. Their IOBT stock forecasts range from $20.00 to $21.00. On average, they expect IO Biotech's stock price to reach $20.50 in the next year. This suggests a possible upside of 355.6% from the stock's current price.
View analysts' price targets for IO Biotech
or view top-rated stocks among Wall Street analysts.

How has IO Biotech's stock performed in 2022?

IO Biotech's stock was trading at $6.40 at the beginning of 2022. Since then, IOBT stock has decreased by 29.7% and is now trading at $4.50.
View the best growth stocks for 2022 here

How were IO Biotech's earnings last quarter?

IO Biotech, Inc. (NASDAQ:IOBT) released its earnings results on Monday, May, 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.06.
View IO Biotech's earnings history

Who are IO Biotech's key executives?

IO Biotech's management team includes the following people:
  • Dr. Mai-Britt Zocca Ph.D., Founder, Pres, CEO, Principal Financial Officer & Director (Age 54, Pay $514.12k)
  • Dr. Muhammad Al-Hajj Ph.D., Chief Scientific Officer (Age 51, Pay $486.63k)
  • Dr. Eva Ehrnrooth M.D., Ph.D., Chief Medical Officer (Age 58, Pay $443.5k)
  • Prof. Inge Marie Svane M.D., Ph.D., Founder & Clinical Advisor
  • Prof. Mads Hald Andersen Ph.D., Founder & Scientific Advisor
  • Anders Ljungqvist, Founder
  • Prof. Per Thor Straten, Founder
  • Mr. Brian Burkavage, VP of Fin. & Chief Accounting Officer (Age 39)
  • Mr. Mikkel Dybkjær, VP of Corp. Fin. (Age 50)
  • Dan Mannix, Sr. VP of Regulatory Affairs

When did IO Biotech IPO?

(IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share.

What is IO Biotech's stock symbol?

IO Biotech trades on the NASDAQ under the ticker symbol "IOBT."

How do I buy shares of IO Biotech?

Shares of IOBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IO Biotech's stock price today?

One share of IOBT stock can currently be purchased for approximately $4.50.

How much money does IO Biotech make?

IO Biotech (NASDAQ:IOBT) has a market capitalization of $129.67 million.

How many employees does IO Biotech have?

IO Biotech employs 19 workers across the globe.

How can I contact IO Biotech?

The official website for IO Biotech is www.iobiotech.com. The company can be reached via phone at 45-7070-2980.

This page (NASDAQ:IOBT) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.